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Abstract
Many key populations have high-risk behaviors for HIV infection making them suitable for HIV vaccine efficacy trials. 
However, these behaviors may change when participants enroll into a trial. We used HIV simulated vaccine efficacy trials 
(SiVETs) nested within observational cohorts of fisherfolks and female sex workers in Uganda to evaluate this difference. We 
screened observational cohort participants for enrolment into SiVETs, until 572 were enrolled. Those not enrolled (n = 953) 
continued participation in the observational cohorts. We determined risk behaviors at baseline and at 1 year, assigned a 
numeric score to each behavior and defined composite score as the sum of reported behaviors. We compared changes in 
scores over 12 months. Both observational cohorts and SiVETs saw a significant decrease in score but greatest in the SiVETs. 
Investigators recruiting for trials from these populations should consider the likely effect of reduction in risk behaviors on 
incident HIV infection and trial statistical power.
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Introduction
According to UNAIDS, 1.8 million new HIV infections 
occurred globally in 2017, 66% of which were in Sub Saha-
ran Africa (SSA) [1]. Available HIV prevention methods 
have had limited effect in curbing new HIV infections in 
SSA because of poor adherence and/or lack of access [2]. 
Three possible long-term hopes for controlling the HIV pan-
demic are an effective and affordable HIV vaccine [3], a 
long-acting drug [4], and antibody injection [5]. Successful 
efficacy trials will need populations with high HIV incidence 
and SSA is likely to be a key destination for many such tri-
als. However, many SSA countries suffer from generalized 
HIV epidemics [6, 7], and although the HIV incidence is 
below 1% per annum [8], the HIV prevalence in the general 
population in Uganda has consistently remained above 5% 
[1]. In such a setting, trials may not be conducted in the 
general population but population sub groups.
Occupational subpopulations, such as Fisherfolks (FF) 
and female sex workers (FSW), are suitable for HIV vaccine 
efficacy trials [9–12]. The incidence of HIV is much higher 
in these subpopulations, with incidence rates as high as 11 
per 100 persons at risk in Uganda [9–14]. These groups have 
shown high willingness to participate in HIV prevention 
research [15, 16] and have good retention in study follow 
up [17, 18]. However, most incidence and retention infor-
mation comes from observational cohorts, and trials often 
have lower HIV incidence than observational cohorts drawn 
from the same population [9, 19, 20]. In 2007/8, lower than 
expected HIV incidence led to the premature termination of 
three microbicides trials in West Africa [20–22].
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Two key reasons have been put forward to explain the 
reduced HIV incidence in trials. First, an inclination for par-
ticipants to reduce risky behaviors due to vigorous trial HIV 
risk-reduction measures. Second, there may be important 
differences between participants who join clinical trials and 
those that do not [20–22]. In such trials, participants have 
reported increased condom use, fewer sexual partners, and 
fewer sex acts compared to their baseline behavior.
To our knowledge, no HIV efficacy trials to date have 
completed follow up among FF on the shoreline of Lake 
Victoria nor among FSW in Kampala. Observational stud-
ies in FF and FSW in Uganda have shown very high HIV 
risk behaviors and genital infections [12, 17, 23–25]. HIV 
incidence in these groups has also been high [12, 14]. As an 
ethical requirement, conduct of HIV vaccine efficacy trials 
requires that participants receive HIV behavioral risk reduc-
tion messages/measures and this is likely to decrease the 
proportion of participants who engage in high-risk behavior.
Composite sets of HIV risk components have been pre-
viously used in cohorts of serodiscordant couples in seven 
African countries [26] and Men who have sex with men in 
China [27], Kenya [28] and Brazil [29], to generate HIV risk 
scores. In these studies, a lower risk score was associated 
with 20 to 85% [26, 29] lower HIV incidence. The composite 
score allowed for more precise predictive capability of risk 
on HIV incidence, than individual predictors [26].
Since 2008, the International AIDS Vaccine Initiative 
(IAVI) in collaboration with MRC/UVRI and LSHTM 
Uganda research Unit have run cohorts of FF and FSW [10, 
11, 17, 18, 24]. Beginning July 2012, HIV simulated vaccine 
efficacy trials (SiVETs) (designed to mimic an HIV vaccine 
efficacy trial using a commercially licensed Hepatitis B vac-
cine) were nested within both cohorts [9, 13]. Results from 
these studies have shown a 50% reduction in HIV incidence 
in the simulation trials compared to the cohorts in which 
they were nested, despite the fact that the licensed vaccine 
has no effect on HIV infection [9, 13].
We use data from the two observational cohorts and the 
nested SiVETs to: (i) determine the proportion of partici-
pants with decreased composite risk score at end of fol-
low up, (ii) compare the decrease in composite risk score 
between the SiVET and the observational cohorts and (iii) 
determine baseline factors associated with decrease in com-
posite risk score.
Methods
Study Design
Data presented in this paper come from two observational 
cohorts,  OBC1 (Jan 2012–Apr 2015) in FF and  OBC2 (Apr 
2008–Apr 2017) in FSW, and two HIV simulated vaccine 
efficacy trials,  SiVET1 (Jul 2012–Apr 2014) nested in  OBC1 
and  SiVET2 (Aug 2014–Apr 2017) nested in  OBC2.
Description of Cohorts
Observational Cohorts Before SiVETs
Eligible Fisherfolks (HIV negative, aged 18–49 years, at 
high risk of HIV infection) were enrolled into  OBC1 at a 
clinic located in Masaka town (100 km Southwest of Kam-
pala, the capital of Uganda) about 50 km inland from the 
fishing communities on Lake Victoria. High risk was defined 
as any one of: multiple or casual sexual partners; presence 
of a sexually transmitted infection; non-condom use with 
causal partner; and alcohol use). Enrolled participants were 
primarily scheduled for quarterly HIV counselling and test-
ing (HCT) and six-monthly HIV behavioral risk assessment. 
 OBC2 enrolled eligible female sex workers (HIV negative, 
aged 18–49 years) at a clinic located in Kampala city about 
2 km from the city center. The follow up schedules and 
reason (HIV incidence and creating a pool of participants 
to enroll in future HIV prevention trials) for establishing 
this cohort were similar to those of  OBC1, except that HIV 
behavioral risk assessment in this cohort was done annually. 
Details of both cohorts have been previously reported [11, 
13, 17, 24, 30].
SiVET Cohorts
From July 2012, participants that had spent between 3 and 
18 months in follow up in  OBC1 were screened for eligibility 
(Table 1) and enrolled into  SiVET1. In addition to the proce-
dures in  OBC1, participants in  SiVET1 were administered a 
commercially licensed hepatitis B vaccine (ENGERIX-BTM 
GlaxoSmithKline Biologicals Rixensart, Belgium) follow-
ing the standard schedule of 0, 1 and 6 months mimicking 
an actual HIV vaccine efficacy trial with extra follow up 
visits (Fig. 1). Similar procedures were followed to establish 
 SiVET2, nested within  OBC2. In both SiVETs, data were 
collected on risk factors, including sexual behaviors at enrol-
ment, 6 and 12 months. The primary purpose of SiVET was 
to determine study participants’ retention at 12 months of 
follow up in a trial environment. Details of both SiVETs 
have been previously reported [9, 13, 30].
Non‑SiVET Cohorts (Observational Cohorts in the SiVET 
Concurrent Period)
Non-SiVET1 in FF and non-SiVET2 in FSW cohorts com-
prised of participants in the respective OBCs that either 
failed the SiVET screening procedure (Table 1 and Fig. 1) 
or who were not enrolled because the SiVET had reached 
its target sample size. In both non-SiVET cohorts, data were 
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collected on sexual behaviors at enrolment, 6 months (only 
non-SiVET1) and 12 months.
HIV Risk Components Score
We defined a composite risk score for each participant tak-
ing account of the following: alcohol consumption; use of 
alcohol prior to sex; number of sexual partners; starting a 
new sexual relationship recently; condom use; and presence 
of genital discharge and/or disease, with scoring as shown 
in Table 2. A higher score indicates higher risk components. 
We used the difference in this composite score between 
baseline and end of follow up (12 months) as a measure 
of change in risk components [29], where a positive value 
indicates an increase in high-risk behavior.
Data Management and Statistical Methods
The data from non-SiVET cohorts were entered and man-
aged in MS Access 2003 (Microsoft Corporation, Red-
mond, WA), and from SiVET cohorts in OpenClinica 
3.5 (Waltham, MA). All data were analyzed in Stata 14.0 
(Stata Corp, College Station, TX, USA). We excluded 
from analysis participants who did not return for at least 
one HIV risk assessment follow-up visit. We summarized 
baseline characteristics using frequencies and percent-
ages and compared them between non-SiVET and SiVET 
cohorts in the same population with chi-square tests. Bar 
graphs were used to display (i) the proportion of partici-
pants reporting each risk component at baseline and at 
12-month follow up and (ii) the proportion of participants 
for each reported risk component who experienced a 
decrease in their risk score from that reported at base-
line. We categorized the score difference into a binary 
variable, 1 for decreased risk component (difference < 0) 
and 0 otherwise (difference ≥ 0). The proportion of par-
ticipants with decreased risk component was estimated as 
the number with difference < 0 divided by the total num-
ber of participants in the analysis expressed as a percent-
age. We estimated the mean and median of the composite 
risk scores at baseline and at 12 months stratified by non-
SiVET and SiVET cohort as well as the study population. 
We fitted linear regression models stratified by the study 
population to determine the relationship of risk score at 
12 months with study (non-SiVET vs SiVET) or other 
baseline characteristics adjusted for baseline risk score. 
After bivariable analyses, a multivariable model was fitted. 
In the multivariable model, factors were removed from the 
model using a backward elimination algorithm retaining 
any factors which remained significant predictor of drop-
ping risk score (p ≤ 0.05) or which caused a change in 
the regression coefficient of 20% or more (i.e., suggesting 
they were a confounding factor). Sex, age group and study 
cohort (SiVET and non-SiVET) were included a priori. 
We preferred linear models to Poisson or negative bino-
mial because the data under consideration did not have any 
zero or skewed scores. However, we further fitted Poisson 
models in a supplementary analysis and similar results 
were observed, Supplementary Table 6.
Two sensitivity analyses were performed: one, stratifying 
the fisherfolk population by gender; the other comparing the 
primary outcome between non-SiVET participants (those 
not screened because of SiVET recruitment accrual) to (a) 
SiVET screen failures and (b) SiVET.
Table 1  Screening and 
enrolment eligibility criteria 
for SiVETs and non-SiVETs 
cohorts
SiVET simulated vaccine efficacy trial, OBC observational cohort
SiVET cohort Non-SiVET cohort
Inclusion
At least 3 and no more than 18 months of follow up in the  OBC1 
or  OBC2
HIV-1 negative and willing to undergo HIV testing
Age 18 to 49 years
Able and willing to provide written informed consent
Able and willing to provide adequate locator information includ-
ing physical address
Willing and able to return for follow-up clinic visits
Intending to reside in study area for at least 1 year
Willing to undergo pregnancy testing
Not breastfeeding and no intent for pregnancy in the next year
Willing to use effective contraception during the study and at least 
3 months after the last vaccination
Inclusion
At least 3 months and no more than 
18 months of follow up in  OBC1 or 
 OBC2
Still in active follow up in the OBCs
HIV-1 negative and willing to undergo 
HIV testing
Exclusion
History of severe allergic reaction to any substance
An acute or chronic illness
Contraindication for Hepatitis B vaccine
Participation in another clinical trial
Hepatitis B positive (only  SiVET2)
Exclusion
HIV positive
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Screened for SiVET 
(n=672)
Eligible for screening into SiVET
(n=1,525)
Screened but not enrolled in SiVET (n=100)
Exposed to Hepatitis B (n=52)
Unwilling to use contraception (n=9)
Pregnant (n=8)
Did not return (n=8)
Other (n=23)
Enrolled into SiVET2
(n=290)
n=231
Remained in non-SiVET2
(n=670)
Enrolled into SiVET1
(n=282)
Non-SiVET cohort 
(n=953)
Hepatitis B vaccine at 0, 1 and  6 months
Post vaccination assessment 30 minutes 
and 3 days later 
HCT at 0,3,6,9  and 12 months 
HIV behavioral risk counselling, 0,3,5,6, 
8, 9 and 12 months  
Promotion and provision of condoms 0,6 
and 12 months  
HIV risk behavior assessment 0, 6 and 
12 months  
Active diagnosis and treatment of genital 
infections 0, 6 and 12 months 
HCT at 0,3,6,9  and 12 months
HIV behavioral risk counselling 
0, 6 (non-SiVET1 only) and 12 
months  
HIV risk behavior assessment 0, 
6 (non-SiVET1 only) and 12 
months 
n=449 n=263 n=240
C
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Remained in non-SiVET1
(n=283)
Screened for observational 
cohorts before SiVET (n=3,828)
Enrolled into observational 
cohorts (n=2,622)
Not enrolled (n=1,206)
Not engaged in sex work, FSW only (n=612) 
Low HIV risk (n=337) 
HIV infection (n=215) 
Other reasons (n=42)
Not eligible for screening into SiVET (n=1,097)
Had been in OBC ≥ 18 months (n=930) 
Exited OBC before SiVET started (n=121) 
HIV infection (n=46)
Fig. 1  Study profile for participants screened and enrolled in SiVET cohorts and those remaining in the non-SiVET cohorts in the FF and FSW 
populations, Uganda
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Results
Screening, Enrolment and Follow Up
In total, 3828 volunteers were screened and 2622 (68%) 
enrolled into observational cohorts before SiVETs, Fig. 1. 
At the start of the SiVET period, 1525 (58%) of those 
enrolled into the original observational cohorts were eli-
gible for screening into SiVETs, 672 (44%) were consecu-
tively screened until 572 (85%) were enrolled. This analysis 
includes data from the 1183 participants who completed at 
least one follow-up behavior assessment visit: 231 (81.6%) 
of the participants in the non-SiVET1 cohort, 449 (65.1%) 
non-SiVET2, 263 (93.3%)  SiVET1 and 240 (82.8%)  SiVET2 
(Fig. 1).
Baseline Characteristics of the Analyzed 
Participants
FF population: From the counts and percentages, compared 
to the non-SiVET1 cohort, the  SiVET1 cohort had more men 
(73% vs 50%), more participants aged 35+ years (25% vs 
14%), more participants engaged in fishing or related occu-
pations (59% vs 45%) and more participants who had lived 
at their current location for more than 1 year (83% vs 70%).
FSW population: From the counts and percentages, 
compared to the non-SiVET2 cohort, the  SiVET2 cohort 
had more participants aged 35+ years (24% vs 14%), more 
with secondary or higher education (44% vs 17%), and more 
participants who had lived at the current location for one 
or more years (85% vs 65%). See Table 3 for more details.
Table 2  HIV risk reduction measures and risk score determination in the non-SiVET and SiVET cohorts in the key populations, Uganda
na not applicable, SiVET simulated vaccine efficacy trial
a Schedule indicated in Fig. 1
Risk reduction measure Study cohort Assessment question Component score
SiVET non-SiVET
HIV counselling and testing Yes Yes HIV test  resultsa na
Counselling on alcohol consumption Yes No Alcohol consumption (last 3 months)a Never (0)
Sometimes (1)
Weekly (2)
Daily (3)
Counselling on having sex under influence 
of alcohol
Yes No Having sex under influence of alcohol (last 
3 months)a
Never (0)
Sometimes (1)
Frequently (2)
Always (3)
Counselling on the number of sexual 
partners
Yes Yes Number of sexual
partners (last 3 months)a
None (0)
One (1)
Two (2)
Three (3)
 ≥ Four (4)
Counselling on having new (casual) sexual 
partners
Yes Yes Number of new sexual partner besides the 
regular (last 3 months)a
None (0)
One (1)
Two (2)
Three (3)
 ≥ Four (4)
Promotion and provision of condoms Yes No (provided on request) Condom use with a new sexual partner 
(last 3 months)a
No new partner (0)
Always (1)
Frequently (2)
Sometimes (3)
Never (4)
Active diagnosis and treatment for genital 
discharge (GD)
Yes Symptomatic treatment Presence of genital  dischargea No (0)
Yes (1)
Active diagnosis and treatment for genital 
ulcer disease (GUD)
Yes Symptomatic treatment Presence of genital ulcer/soresa No (0)
Yes (1)
Total least score = 0 while the maximum worst score = 20
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Risk Indicator Characteristics at Baseline 
and 12 Months
Reported participant behavior/characteristics at baseline 
and 12 months are shown in the bar graph, Fig. 2. For 
the FF population, the baseline components were broadly 
comparable between the non-SiVET1 and  SiVET1 cohorts, 
except for the proportion of participants reporting more 
than one sexual partner, which was higher in the  SiVET1 
(71%) compared to the non-SiVET1 (57%). At 12 months 
of follow up, the two groups were largely similar, except 
for having genital ulcer/sores (20% vs 10%), reporting new 
sexual partners (46% vs 37%) and non-condom use with 
new sexual partner (52% vs 37%) that were all higher in 
non-SiVET1 compared to  SiVET1. Similarly, in the FSW 
population the baseline components were comparable 
Table 3  Baseline characteristics of participants in the non-SiVET and SiVET cohorts in the key populations in Uganda, counts, percentages and 
chi-squared test
FF Fisherfolk, FSW female sex worker, SiVET simulated vaccine efficacy trial
Variable Total (%) FF (N = 494) FSW (N = 689)
Non-SiVET1
n (%)
SiVET1
n (%)
p-value Non-SiVET2
n (%)
SiVET2
n (%)
p-value
Overall 1183 (100) 231 (100) 263 (100) 449 (100) 240 (100)
Sex  < 0.01
 Male 306 (26) 115 (50) 191 (73) – –
 Female 877 (74) 116 (50) 72 (27) 449 (100) 240 (100)
Age (years) 0.01  < 0.01
 18–24 440 (37) 104 (45) 79 (30) 191 (43) 66 (28)
 25–34 522 (44) 94 (41) 119 (45) 193 (43) 116 (48)
 35+ 221 (19) 33 (14) 65 (25) 65 (14) 58 (24)
Ethnicity 0.02 0.07
 Baganda 544 (46) 94 (41) 121 (46) 204 (45) 125 (52)
 Banyankole 170 (14) 40 (17) 27 (10) 76 (17) 27 (11)
 Banyarwanda 150 (13) 59 (26) 53 (20) 21 (5) 17 (7)
 Other 319 (27) 38 (16) 62 (24) 148 (33) 71 (30)
Religion 0.36 0.98
 Christian 899 (76) 172 (74) 205 (78) 340 (76) 182 (76)
 Muslim 284 (24) 59 (26) 58 (22) 109 (24) 58 (24)
Education 0.12  < 0.01
 None 237 (20) 25 (11) 17 (6) 182 (41) 13 (5)
 Primary 666 (56) 156 (67) 197 (75) 191 (42) 122 (51)
 Secondary+ 280 (24) 50 (22) 49 (19) 76 (17) 105 (44)
Marital status 0.24 0.01
 Single never married 359 (31) 67 (29) 75 (29) 158 (35) 59 (25)
 Married 275 (23) 104 (45) 135 (51) 24 (5) 12 (5)
 Single ever married 549 (46) 60 (26) 53 (20) 267 (60) 169 (70)
Occupation < 0.01 0.22
 Small scale business 147 (12) 54 (23) 70 (27) 13 (3) 10 (4)
 Fishing/related 259 (22) 104 (45) 155 (59) – –
 Hotel/bar/hair saloon 298 (25) 41 (18) 22 (8) 144 (32) 91 (38)
 Sex work 425 (36) – – 289 (64) 136 (57)
 Other 54 (5) 32 (14) 16 (6) 3 (1) 3 (1)
Duration (years) in community < 0.01  < 0.01
 0–1 306 (26) 70 (30) 44 (17) 156 (35) 36 (15)
 > 1 877 (74) 161 (70) 219 (83) 293 (65) 204 (85)
Illicit drug use 0.53 0.95
 No 572 (48) 207 (90) 231 (88) 87 (19) 47 (20)
 Yes 611 (52) 24 (10) 32 (12) 362 (81) 193 (80)
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between the non-SiVET2 and  SiVET2 populations, except 
for reported daily alcohol use (58% vs 28%), genital ulcer/
sores (39% vs 16%) and non-condom use with new sex-
ual partner (26% vs 1%) that were all higher in the non-
SiVET2 (Fig. 2). At 12 months of follow up, the differ-
ences between non-SiVET2 and  SiVET2 seen at baseline 
remained.
Composite Risk Score
The composite risk scores for each cohort, and stratified 
by study population, are shown by means and medians in 
Table 4. In both cohorts, the mean risk score was higher in 
the SiVET than the corresponding non-SiVET at baseline; 
in the FF population, this situation had reversed in the 
12 months of follow up.
Decrease in Risk Score Between Baseline 
and 12 Months of Follow‑Up
Overall, 170 (73.6%) of the participants in the non-SiVET1 
and 214 (81.4%) in the  SiVET1 cohort in the FF popula-
tion experienced a decrease in risk score (p = 0.038). Simi-
larly, 197 (43.9%) of the participants in the non-SiVET2 
compared to 149 (62.1%) in  SiVET2 cohort in the FSW 
population experienced a decrease in risk score, p < 0.001.
The bar graph, Fig.  3 shows the proportion of par-
ticipants whose individual component risk scores at 
12  months decreased from that at baseline. In the FF 
population, there was generally a large decrease, of 40% 
or more, in the risk score for all components in both 
non-SiVET1 and  SiVET1. The difference between non-
SiVET1 and  SiVET1 cohorts were observed mainly in the 
M0 M12 M0 M12 M0 M12 M0 M12
Daily alcohol use (%) 7 4 11 8 58 58 28 29
Alcohol use before sex (%) 2 2 3 1 1 1 6 0
Genital discharge (%) 51 18 42 16 23 20 29 20
Genital ulcer/sores (%) 41 20 43 10 39 34 16 12
>1 sexual partners (%) 57 27 71 35 92 91 99 83
Having a new sexual partner (%) 69 46 76 37 79 80 92 74
Non condom use with new partner (%) 65 52 65 37 26 30 1 3
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M-Month of follow up
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Fig. 2  Proportion of risk component measures at baseline and 12 months in the non-SiVET and SiVET cohorts among the key populations in 
Uganda
Table 4  Risk score at baseline 
and 12 months of follow up 
stratified by study cohort and 
population (means and medians)
FF Fisherfolk, FSW female sex worker, SiVET simulated vaccine efficacy trial, SD standard deviation, IQR 
interquartile range
Population Study Risk score at baseline Risk score at 12 months
Mean SD Median IQR Mean SD Median IQR
FF Non-SiVET1 7.7 3.9 8 5–10 5.1 3.6 4 2–7
SiVET1 8.8 3.6 9 6–11 4.8 3.2 5 2–7
FSW Non-SiVET2 8.7 2.7 9 7–10 8.5 2.5 9 7–10
SiVET2 11.4 3.1 9 8–13 9.5 3.8 10 7–12
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proportion with decreased genital ulcer/sores (53% vs 
77%) and those reporting new sexual partners (51% vs 
73%).
In the FSW population there were generally smaller 
decreases (typically less than 15%) in the risk score in the 
non-SiVET2 for most components except for genital ulcer/
sores and non-condom use with a new sexual partner that 
declined by about 40%. On the other hand, the decreases in 
risk score were over 30% for all components in the  SiVET2 
cohort. Comparing non-SiVET2 to  SiVET2, the propor-
tion of decreased risk score were higher in  SiVET2 for all 
components.
Regression Analysis of Risk Score at 12 Month
Table 5 shows the results of linear regression models 
comparing non-SiVET to corresponding SiVET cohort at 
12 months of follow up adjusted for baseline risk score 
and other factors shown in the table. Overall, in the FF 
population, the predicted mean risk score for  SiVET1 at 
12 months was 0.63 points lower (95% CI – 1.18 to – 0.08, 
p = 0.024) than for non-SiVET1 after adjustment for fac-
tors shown in Table 5. In FSW it was 0.10 points lower 
(95% CI – 0.58 to 0.39, p = 0.692) for  SiVET2 than non-
SiVET2 after adjusting for factors shown in Table 5. In the 
FF population, the predicted mean risk score for females 
was 1.65 points lower (95% CI – 2.24 to – 1.05, p < 0.001) 
than males.
Results of the sensitivity analyses
Linear regression models comparing non-SiVET partici-
pants (not screened because of SiVET recruitment accrual) to 
SiVET and SiVET screen failures and adjusting for the factors 
in Table 5 were applied separately to each of the two sub-
populations. Compared to the non-SiVET participants in the 
FF population; the predicted mean risk score was 0.75 points 
lower (95% CI – 1.31 to – 0.20, p = 0.004) in SiVET partici-
pants, and 1.94 lower (95% CI – 3.60 to – 0.29, p = 0.021) 
in SiVET screen failures. Similarly, in the FSW compared to 
non-SiVET participants, the predicted mean risk score was 
0.05 points lower (95% CI – 0.57 to 0.46, p = 0.836) in SiVET 
participants but 0.52 points higher (95% CI – 0.27 to 1.32, 
p = 0.198) in the SiVET screen failures.
In a further sensitivity analysis of the adjusted linear regres-
sion models stratified by sex in the FF population, comparing 
non-SiVET participants to SiVET ones, the predicted mean 
risk score for SiVET was 1.24 points lower (95% CI – 2.01 
to – 0.48, p = 0.002) for the men and 0.67 points lower (95% 
CI – 1.41 to – 0.08, p = 0.080) for the women. All results and 
adjustment risk factors are shown in Supplementary Table 7.
Discussion
In this paper, we compared behaviors of people recruited 
into simulated HIV vaccine efficacy trials with people who 
remained in the observational cohorts in which the trials 
Non-SiVET1 SiVET1 Non-SiVET2 SiVET2
Daily alcohol use (%) 46 43 2 38
Alcohol use before sex (%) 52 53 4 51
Genital discharge (%) 61 68 14 50
Genital ulcer/sores (%) 53 77 41 53
>1 sexual partners (%) 45 59 1 30
Having a new sexual partner (%) 51 73 14 32
Non condom use with new partner (%) 46 52 42 58
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Fig. 3  Proportion of participants with decrease in the score of a given risk component measure between baseline and 12 months among the key 
populations in Uganda
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Table 5  Unadjusted and adjusted factors associated with decrease in risk score among key populations in Uganda, linear regression models 
results
Variable FF (N = 494) FSW (N = 689)
Uncoef (95%CI) p-value aCoef (95%CI) p-value Uncoef (95%CI) p-value aCoef (95%CI) p-value
Study
 Non-SiVET Ref Ref Ref Ref
 SiVET – 0.63 (– 1.18 to 
– 0.08)
0.024 – 0.92 (– 1.47 to 
– 0.37)
0.001 – 0.10 (– 0.58 to 
0.39)
0.692 – 0.12 (0.63 to 
0.38)
0.625
Sex
 Male Ref Ref – – – – 
 Female – 1.55 (– 2.11 to 
– 0.98)
 < 0.001 – 1.65 (– 2.24 to 
– 1.05)
 < 0.001
Age (years)
 18–24 Ref Ref Ref Ref
 25–34 0.25 (– 0.36 to 
0.86)
0.425 0.09 (– 0.51 to 
0.69)
0.764 0.09 (– 0.38 to 
0.56)
0.697 0.09 (– 0.41 to 
0.59)
0.729
 35 + – 0.23 (– 0.99 to 
0.52)
0.544 – 0.24 (– 0.99 to 
0.50)
0.522 0.07 (– 0.54 to 
0.69)
0.810 0.14 (– 0.52 to 
0.79)
0.686
Ethnicity
 Baganda Ref Ref Ref
 Banyankole 0.65 (– 0.20 to 
1.50)
0.132 0.43 (– 0.40 to 
1.25)
0.310 – 0.26 (– 0.89 to 
0.36)
0.412
 Banyarwanda – 0.26 (– 0.96 to 
0.45)
0.478 – 0.14 (– 0.83 to 
0.55)
0.694 – 0.09 (– 1.04 to 
0.86)
0.849
 Other 0.39 (1.13 to 2.55) 0.300 0.22 (– 0.50 to 
0.93)
0.553 0.35 (– 0.14 to 
0.83)
0.159
Religion
 Christian Ref Ref
 Muslim – 0.31 (– 0.96 to 
0.33)
0.337 – 0.01 (– 0.51 to 
0.49)
0.968
Education
 None Ref Ref
 Primary – 0.10 (– 1.09 to 
0.89)
0.842 0.26 (– 0.25 to 
0.77)
0.317
 Secondary + – 0.55 (– 1.67 to 
0.57)
0.337 – 0.15 (– 0.72 to 
0.43)
0.614
Marital status
 Single never mar-
ried
Ref Ref Ref
 Married – 0.42 (– 1.07 to 
0.22)
0.197 – 1.03 (– 2.03 to 
– 0.04)
0.042 – 1.15 (– 2.17 to 
– 0.14)
0.026
 Single ever mar-
ried
– 0.29 (– 1.05 to 
0.47)
0.456 0.003 (– 0.46 to 
0.46)
0.989 – 0.14 (– 0.65 to 
0.37)
0.599
Occupation
 Small scale busi-
ness
Ref Ref Ref
 Fishing/related 0.64 (– 0.03 to 
1.31)
0.060 – – 
 Hotel/bar/salon – 0.37 (– 1.30 to 
0.56)
0.434 – 0.59 (– 1.80 to 
0.62)
0.339 – 0.56 (– 1.78 to 
0.66)
0.368
 Sex work – 0.21 (– 1.40 to 
0.97)
0.726 – 0.16 (– 1.35 to 
1.04)
0.798
 Other – 0.48 (– 1.50 to 
0.55)
0.360 – 1.33 (– 3.87 to 
1.21)
0.304 – 1.27 (– 3.82 to 
1.27)
0.326
Duration (years) in community
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were nested. The cohorts consisted of fisherfolks and female 
sex workers in Uganda. We found that the proportion of 
participants whose composite HIV risk score decreased was 
higher among participants who enrolled in SiVETs. Gener-
ally, the proportion of participants with decreased risk score 
were lower among FSW than FF; conversely, the difference 
between SiVET and non-SiVET cohorts was greatest in 
the FSW population. The results from the linear regression 
analysis suggested that participation in a SiVET was inde-
pendently associated with a decrease in composite risk score 
in both populations; however, there was only good statistical 
evidence for this among FF. This result is consistent with 
previous trials, which reported participants’ engagement in 
lower HIV risky behaviors during trial follow up beyond that 
observed in the source population [20–22].
In the FF population, women were more likely than men 
to report a decrease in HIV risk behaviors. Literature shows 
that women in Sub Saharan Africa [31] have better health 
seeking behaviors and they could have been more likely to 
respond to the HIV risk reduction measures provided in 
these cohorts.
Although the observational cohorts were the recruit-
ment source for the SiVETs, screening and enrollment was 
consecutive and not random; thus participants’ baseline 
characteristics between SiVET and non-SiVET cohorts dif-
fered in some important ways in both populations. SiVETs 
recruited more men  (SiVET1 in FF), more participants aged 
35 or over, more educated participants  (SiVET2 in FSW) 
and more people who had lived in the community for longer 
than 1 year. Previous studies have highlighted the signifi-
cant selection differences between clinical trials and source 
population and its effect on the trial outcomes [19–21, 32].
Clinical trials of active interventions have shown a 50% 
to 78% reduction in HIV incidence in the control arm com-
pared to that predicted from the source population [20–22]. 
This led to many of these trials ending early due to futility. 
Similarly, previous publications from these SiVETs [9, 13] 
in FF and FSW populations have indicated a 40% to 50% 
reduction in HIV incidence in those recruited into the trial 
compared to the source population, even though the Hepa-
titis B vaccine used in the SiVETs had no effect on HIV 
susceptibility.
It is possible that consecutive screening and enrolment 
into SiVET included more of the participants that were 
likely to report on time for study visits and adhere to HIV 
risk reduction measures. The engagement with less risky 
behaviors might lower the risk for HIV infection in inter-
vention trials for reasons unrelated to the product being 
tested. In the FF population, individual HIV risk compo-
nents generally decreased between baseline and 12 months, 
more so in the SiVET cohorts. More notable was a decrease 
in ‘condomless’ sex with a new sexual partner. This was 
more marked in the SiVET, about 43% decrease as opposed 
to 20% in non-SiVET cohort. Though not documented at 
interim clinic visits, SiVET participants had more access to 
condoms because of the more clinic visits.
On the other hand, in the FSW population, there were 
marginal decreases in individual reported risk behavior in 
the SiVET cohort and very minimal to none in the non-
SiVET cohort. This could be associated with the occupa-
tional demands of sex work as the livelihood of 100% of 
these cohort participants depended on high-risk behavior. 
Unlike the FF population, the FSW population was com-
prised of females and only male condoms were provided for 
use with male sexual clients. Literatures in Africa shows 
that, females have limited power in relationships to demand 
condom use [33]. Furthermore, studies in female sex work-
ers population in Africa [34] and elsewhere [35–37] have 
shown that ‘condomless’ sex attracted more pay. This could 
hamper decreases in ‘condomless’ sex with new or other 
causal sexual partners as seen in this population.
Our analysis has a number of strengths that included 
a reasonable sample size, two distinct key populations 
in which SiVET and non-SiVET cohorts were aligned to 
a set duration of time. Both SiVET and corresponding 
non-SiVET cohorts’ participants were seen at the same 
FF Fisherfolk, FSW female sex worker, SiVET simulated vaccine efficacy trial, CI confidence interval, Uncoef unadjusted linear regression 
model coefficient, aCoef adjusted linear regression model coefficient, p value statistical significance, Ref reference category
Table 5  (continued)
Variable FF (N = 494) FSW (N = 689)
Uncoef (95%CI) p-value aCoef (95%CI) p-value Uncoef (95%CI) p-value aCoef (95%CI) p-value
 0–1 Ref Ref Ref
 > 1 0.41 (– 0.24 to 
1.05)
0.217 0.30 (– 0.17 to 
0.77)
0.213 0.31 (– 0.18 to 
0.80)
0.209
Illicit drug use
 No Ref Ref Ref
 Yes 1.06 (0.19–1.94) 0.017 0.78 (– 0.07 to 
1.63)
0.073 – 0.29 (– 0.82 to 
0.24)
0.288
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clinic by the same study staff under standardized study 
procedures. All staff were trained on both studies, and 
study visits and conduct were done per Standard Oper-
ating Procedures to assure data were collected in a sys-
tematic manner. Our comparative analysis is not without 
limitations, however. SiVET cohorts were more likely to 
screen and enroll participants that reported on time for 
their 3 to 18 months source cohort clinic visit. It is pos-
sible that timely participants are also more inclined to 
take up the HIV behavioral risk reduction measures or 
are otherwise more compliant with study instructions. The 
study procedures in the SiVET and non-SiVET cohorts 
were not blinded. However, at the time of the conduct of 
SiVETs, the primary aim was not to compare SiVET to 
non-SiVET participants and if there were any differences 
in the conduct of study procedures, they were likely mod-
est unconscious biases, and are unlikely to have affected 
the outcomes considered in this analysis. Participants were 
encouraged to take more condoms in case their stock was 
finished before the next scheduled clinic visits and we did 
not document the data on condom demands on visits that 
HIV risk behavior assessment was not scheduled. This 
could have helped explain the more marked increase in 
condom use with a new sexual partner seen in the SiVETs 
cohort because participants in this cohort had more of such 
visits. Notwithstanding these limitations, our comparative 
analysis gives a rare opportunity of estimating the likely 
drop in HIV risk components in trials nested within source 
cohorts in two distinct key populations.
In conclusion, results from both key populations suggest 
that participation in both studies positively affected risk-tak-
ing behavior, and in some cases, this was more pronounced 
in a “Simulation trial” conducted alongside an observational 
study aligned to the same duration of time. Previous publi-
cations from these populations have shown lower HIV inci-
dence in SiVET cohorts compared to non-SiVET cohorts 
even when aligned to the same duration of follow up. Other 
studies have also shown lower HIV incidence in the trial 
control arm compared to that predicted from observational 
data at the trial on set. Therefore, it is likely that participants 
who join trials are mostly those likely to respond to HIV risk 
reduction measures beyond what is seen in source population 
or the general population. While the more than half drop in 
the HIV risk score in FF and one third in FSW participating 
in SiVETs is of great public health importance, investigator-
recruiting participants into clinical trials from observational 
cohorts in these key populations need to consider the likely 
effect of reduction in HIV risk components on likelihood 
of seroconversion and the trial statistical power. Taking the 
results of this analysis and previous publications on HIV 
incidence from these SiVETs and non-SiVET cohorts, it is 
encouraging that these key populations could still be suitable 
for HIV vaccine efficacy and other HIV prevention trials.
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